Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children

Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600 Furlan M, Robles R, Lamie B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234 Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–4244 Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584 Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594 Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035–1050 Tsai HM (2006) The molecular biology of thrombotic microangiopathy. Kidney Int 70:16–23 Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G (2006) Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279 Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschênes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400 Kavanagh D, Richards A, Atkinson JP (2008) Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 59:293–309 Sadler JE (2005) von Willebrand factor: two sides of a coin. J Thromb Haemost 3:1702–1709 Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K (1985) Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 38:469–479 Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666 Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063 Veyradier A, Meyer D (2005) Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 3:2420–2427 Sadler JE (2006) Thrombotic thrombocytopenic purpura: a moving target. Hematology Am Soc Hematol Educ Program 415–420 Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, Funato M, Matsui T, Titani K, Yagi H, Matsumoto M, Fujimura Y (2001) Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 74:101–108 Schulman I, Pierce M, Lukens A, Currimbhoy Z (1960) Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 16:943–957 Upshaw JD Jr (1978) Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 298:1350–1352 Sasahara Y, Kumaki S, Ohashi Y, Minegishi M, Kano H, Bessho F, Tsuchiya S (2001) Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome. Int J Hematol 74:109–114 Kentouche K, Budde U, Furlan M, Scharfe V, Schneppenheim R, Zintl F (2002) Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr 91:1056–1059 Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y (2002) Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 99:11902–11907 Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lammle B, Scheiflinger F (2003) ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 120:821–824 Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, van de Kar N, Monnens L, van den Heuvel L (2003) Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 63:1995–1999 Bestetti G, Stellari A, Lattuada A, Corbellino M, Parravicini C, Calzarossa C, Cenzuales S, Moroni M, Galli M, Rossi E (2003) ADAMTS 13 genotype and vWF protease activity in an Italian family with TTP. Thromb Haemost 90:955–956 Savasan S, Lee SK, Ginsburg D, Tsai HM (2003) ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 101:4449–4451 Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, Hassenpflug W, Haberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel D, Obser T, Santer R, Sykora KW (2003) Von Willebrand factor cleaving protease and ADAMTS 13 mutations in childhood TTP. Blood 101:1845–1850 Kokame K, Miyata T (2004) Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 41:34–40 Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B (2004) Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int 66:955–958 Matsumoto M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, Iwai A, Ito E, Tsuji Y, Takeda-Shitaka M, Iwadate M, Umeyama H, Yagi H, Ishizashi H, Banno F, Nakagaki T, Miyata T, Fujimura Y (2004) Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 103:1305–1310 Schneppenheim R, Budde U, Hassenpflug W, Obser T (2004) Severe ADAMTS-13 deficiency in childhood. Semin Hematol 41:83–89 Uchida T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano T, Suzuki M, Matsubara Y, Soejima K, Matsumoto M, Fujimura Y, Ikeda Y, Murata M (2004) Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 104:2081–2083 Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP (2004) Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2:424–429 Lowe EJ, Werner EJ (2005) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in children and adolescents. Semin Thromb Hemost 31:717–730 Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D (2006) Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost 32:90–97 Peyvandi F, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro R, Rossi E, Mannuccio Mannucci P (2006) Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 27:330–336 Shibagaki Y, Matsumoto M, Kokame K, Ohba S, Miyata T, Fujimura Y, Fujita T (2006) Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol Dial Transplant 21:1289–1292 Tao Z, Anthony K, Peng Y, Choi H, Nolasco L, Rice L, Moake JL, Dong JF (2006) Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 4:1931–1935 Motto D, Levy G, Mcgee B, Tsai HM, Ginsburg D (2003) ADAMTS13 mutations identified in familial TTP patients result in loss of VWF-cleaving protease activity. J Thromb Haemost 1(Suppl):OC115 Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ (2004) Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 279:21439–21448 Plaimauer B, Fuhrmann J, Mohr G, Wernhart W, Bruno K, Ferrari S, Konetschny C, Antoine G, Rieger M, Scheiflinger F (2006) Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 107:118–125 Donadelli R, Banterla F, Galbusera M, Capoferri C, Bucchioni S, Gastoldi S, Nosari S, Monteferrante G, Ruggeri ZM, Bresin E, Scheiflinger F, Rossi E, Martinez C, Coppo R, Remuzzi G, Noris M (2006) In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS 13 in thrombotic thrombocytopenic purpura. Thromb Haemost 96:454–564 Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D (2007) ADAMTS 13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 166:249–257 Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Böhm M, Plaimauer B, Lämmle B, Scheiflinger F (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106:1262–1267 Ashida A, Nakamura H, Yoden A, Tamai H, Ishizashi H, Yagi H, Matsumoto M, Fujimura Y (2002) Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome. Am J Hematol 71:318–322 Robson WL, Tsai HM (2002) Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy. Pediatrics 109:322–325 Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH (2003) Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol 25:336–339 Curtillet C, Poullin P, Doré E, Fossat C, Lefevre P, Michel G (2006) Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura. Arch Pediatr 13:1521–1524 Veyradier A, Girma JP (2004) Assays of ADAMTS13 activity. Semin Hematol 41:41–47 Kokame K, Matsumoto M, Fujimura Y, Miyata T (2004) VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 103:607–612 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100 Hommais A, Rayes J, Houllier A, Obert B, Legendre P, Veyradier A, Girma JP, Ribba AS (2007) Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura. Thromb Haemost 98:593–599 Zhou W, Bouhassira EE, Tsai HM (2007) An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers. Blood 110:886–893 Schmugge M, Dunn MS, Amankwah KS, Blanchette VS, Freedman J, Rand ML (2004) The activity of the von Willebrand factor cleaving protease ADAMTS-13 in newborn infants. J Thromb Haemost 2:228–233 Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A (2007) Prognostic value of anti-ADAMTS13 antibodies features (Ig isotype, titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity. Blood 109:2815–2822 Deschênes G, Veyradier A, Cloarec S, Benoit S, Desbois I, Gruel Y, Nivet H (2002) Plasma therapy in von Willebrand factor protease deficiency. Pediatr Nephrol 17:867–870 Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, Lesure F, Delattre P, Lakhdari M, Meyer D, Girma JP, Loirat C (2003) Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 14:310–317 Jamshed S, Kouides P, Sham R, Cramer S (2007) Pathology of thrombotic thrombocytopenic purpura in the placenta, with emphasis on the snowman sign. Pediatr Dev Pathol 10:455–462 Furlan M, Lammle B (2001) Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 14:437–454 Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS 13 deficiency and renal involvement. J Am Soc Nephrol 16:1177–1183 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89:3097–3103 Zheng XL, Sadler JE (2008) Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 3:249–277 Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D (2005) Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS 13-deficient mice. J Clin Invest 115:2752–2761 Chak WK, Lam DS, Lo WH, Hui CM, Wong SN (2000) Thrombotic thrombocytopenic purpura as a rare complication in childhood systemic lupus erythematosus: case report and literature review. Hong Kong Med J 9:363–368 Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K (2004) Severe ADAMTS 13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83:233–244 Coppo P, Veyradier A, Monge M (2006) Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease. Presse Med 35:1876–1886 George JN, Vesely SK, Terrell DR (2004) The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 41:60–67 Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pene F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B (2006) Prognostic value of inhibitory anti-ADAMTS 13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 132:66–74 Rock GA (2000) Management of thrombotic thrombocytopenic purpura. Br J Haematol 109:496–507 Fontana S, Hovinga JA, Studt JD, Alberio L, Lammle B, Taleghani BM (2004) Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol 41:48–59 Furlan M, Robles R, Morselli B, Sandoz P, Lammle B (1999) Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 81:8–13 Rock G, Yousef H, Neurath D, Lu M (2006) ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma. Transf Apher Sci 35:235–238 Heger A, Kannicht C, Römisch J, Svae TE (2007) Normal levels of ADAMTS 13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 92:206–212 Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD (2007) Comparison and stability of ADAMTS 13 activity in therapeutic plasma products. Transfusion 47:120–125 Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG (2004) Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Am J Hematol 77:387–390 George JN (2007) Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med 22:82–91 Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, Wu HM (2007) Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS 13 activity. Br J Haematol 139:486–493 Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS 13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932–1937 George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK (2006) Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21:49–56 Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97:228–233 Rüfer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lämmle B, Wuillemin WA (2007) Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly 137:518–524 Brodin-Sartorius A, Guebre-Egziabher F, Fouque D, Cozon G, Villar E, Laville M, Juillard L (2006) Recurrent idiopathic thrombotic thrombocytopenic purpura: a role for vaccination in disease relapse? Am J Kidney Dis 48:e31–e34 Reiter RA, Knobl P, Varadi K, Turecek PL (2003) Changes in von Willebrand factor-cleaving protease (ADAMTS 13) activity after infusion of desmopressin. Blood 101:946–948 Mannucci PM, Capoferri C, Canciani MT (2004) Plasma levels of von Willebrand factor regulate ADAMTS 13, its major cleaving protease. Br J Haematol 126:213–218 Hara T, Kitano A, Kajiwara T, Kondo T, Sakai K, Hamasaki Y (1986) Factor VIII concentrate-responsive thrombocytopenia, haemolytic anemia, and nephropathy. Evidence that factor VIII: von Willebrand factor is involved in its pathogenesis. Am J Pediatr Hematol Oncol 8:324–328 Veyradier A, Meyer D, Loirat C (2006) Desmopressin, an unexpected link between nocturnal enuresis and inherited thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 4:700–701 Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, Pinomäki A, Armstrong E, Koivusalo A, Tukiainen E, Mäkisalo H, Saland J, Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS (2008) Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 8:216–221